Luteolin
In clinical developmentAlso known as Digitoflavone, Flacitran, Salifazide, Luteoline+1 more
Digitoflavone, Flacitran, Salifazide, Luteoline, Luteolol.
Recent clinical, regulatory, research and industry developments relating to this drug.
Flavonols and Flavones as Potential anti-Inflammatory, Antioxidant, and Antibacterial Compounds.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Oxidative medicine and cellular longevity1
- Behrens MD1
- Chagas MDSS1
- Gonçalves-de-Albuquerque CF1
- Moragas-Tellis CJ1
- Penedo GXM1
- Silva AR1
- Instituto de Biologia1
- Instituto de Tecnologia em Fármacos - Farmanguinhos1
- Instituto Oswaldo Cruz1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials